Identification

Name
Butorphanol
Accession Number
DB00611  (APRD00835)
Type
Small Molecule
Groups
Approved, Illicit, Vet Approved
Description

A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain. [PubChem]

Structure
Thumb
Synonyms
  • (-)-17-(Cyclobutylmethyl)morphinan-3,14-diol
  • (-)-Butorphanol
  • (-)-N-Cyclobutylmethyl-3,14-dihydroxymorphinan
  • Butorfanol
  • Butorphanol
  • Butorphanolum
External IDs
BC-2627 / levo-BC 2627 / LEVO-BC-2627
Product Ingredients
IngredientUNIICASInChI Key
Butorphanol Tartrate2L7I72RUHN 58786-99-5GMTYREVWZXJPLF-AFHUBHILSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Butorphanol Nasal SpraySolution10 mgNasalAa Pharma Inc2000-08-01Not applicableCanada
PMS-butorphanolSpray10 mgNasalPharmascience Inc2002-06-07Not applicableCanada
Stadol NS - 10mg/ml Aem-liqAerosol, metered; Liquid10 mgNasalBristol Myers Squibb1994-12-312004-08-04Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Butorphanol TartrateInjection, solution2 mg/mLIntramuscular; IntravenousHospira, Inc.1997-01-23Not applicableUs
Butorphanol TartrateSpray, metered10 mg/mLNasalA S Medication Solutions2002-03-122017-06-20Us
Butorphanol TartrateSpray, metered10 mg/mLNasalWest Ward Pharmaceutical2002-03-12Not applicableUs
Butorphanol TartrateInjection, solution1 mg/mLIntramuscular; IntravenousHospira, Inc.1997-01-23Not applicableUs
Butorphanol TartrateSpray10 mg/mLNasalApotex Corporation2002-12-04Not applicableUs
Butorphanol TartrateInjection2 mg/mLIntramuscular; IntravenousCardinal Health1998-10-15Not applicableUs
Butorphanol TartrateInjection, solution1 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical2009-05-01Not applicableUs
Butorphanol TartrateSpray10 mg/mLNasalMylan Pharmaceuticals2011-01-21Not applicableUs
Butorphanol TartrateInjection1 mg/mLIntramuscular; IntravenousCardinal Health1998-10-15Not applicableUs
Butorphanol TartrateInjection, solution2 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines2013-08-14Not applicableUs
International/Other Brands
Butaro (Lotus Pharmaceuticals) / Butrum (Aristo) / Stadol (Bristol-Myers Squibb) / Stadol NS (Cephalon)
Categories
UNII
QV897JC36D
CAS number
42408-82-2
Weight
Average: 327.4605
Monoisotopic: 327.219829177
Chemical Formula
C21H29NO2
InChI Key
IFKLAQQSCNILHL-QHAWAJNXSA-N
InChI
InChI=1S/C21H29NO2/c23-17-7-6-16-12-19-21(24)9-2-1-8-20(21,18(16)13-17)10-11-22(19)14-15-4-3-5-15/h6-7,13,15,19,23-24H,1-5,8-12,14H2/t19-,20+,21-/m1/s1
IUPAC Name
(1S,9R,10S)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.0¹,¹⁰.0²,⁷]heptadeca-2(7),3,5-triene-4,10-diol
SMILES
[H][[email protected]@]12CC3=C(C=C(O)C=C3)[[email protected]]3(CCCC[[email protected]@]13O)CCN2CC1CCC1

Pharmacology

Indication

For the relief of moderate to severe pain.

Structured Indications
Pharmacodynamics

Butorphanol is a synthetic opioid agonist-antagonist analgesic with a pharmacological and therapeutic profile that has been well established since its launch as a parenteral formulation in 1978. The introduction of a transnasal formulation of butorphanol represents a new and noninvasive presentation of an analgesic for moderate to severe pain. This route of administration bypasses the gastrointestinal tract, and this is an advantage for a drug such as butorphanol that undergoes significant first-pass metabolism after oral administration. The onset of action and systemic bioavailability of butorphanol following transnasal delivery are similar to those after parenteral administration. Butorphanol blocks pain impulses at specific sites in the brain and spinal cord.

Mechanism of action

The exact mechanism of action is unknown, but is believed to interact with an opiate receptor site in the CNS (probably in or associated with the limbic system). The opiate antagonistic effect may result from competitive inhibition at the opiate receptor, but may also be a result of other mechanisms. Butorphanol is a mixed agonist-antagonist that exerts antagonistic or partially antagonistic effects at mu opiate receptor sites, but is thought to exert its agonistic effects principally at the kappa and sigma opiate receptors.

TargetActionsOrganism
AKappa-type opioid receptor
agonist
Human
ADelta-type opioid receptor
agonist
Human
AMu-type opioid receptor
partial antagonist
Human
Absorption

Rapidly absorbed after intramuscular injection and peak plasma levels are reached in 20-40 minutes. The absolute bioavailability is 60-70% and is unchanged in patients with allergic rhinitis. In patients using a nasal vasoconstrictor (oxymetazoline) the fraction of the dose absorbed was unchanged, but the rate of absorption was slowed. Oral bioavailability is only 5-17% because of extensive first-pass metabolism.

Volume of distribution
  • 305 to 901 L
Protein binding

Serum protein binding is approximately 80%.

Metabolism

Extensively metabolized in the liver. The pharmacological activity of butorphanol metabolites has not been studied in humans; in animal studies, butorphanol metabolites have demonstrated some analgesic activity.

Route of elimination

Butorphanol is extensively metabolized in the liver. Elimination occurs by urine and fecal excretion.

Half life

The elimination half-life of butorphanol is about 18 hours. In renally impaired patients with creatinine clearances <30 mL/min the elimination half-life is approximately doubled. After intravenous administration to patients with hepatic impairment, the elimination half-life of butorphanol was approximately tripled.

Clearance
  • 99 +/- 23 L/h [Young with IV 2 mg]
  • 82 +/- 21 [Eldery with IV 2 mg]
Toxicity

The clinical manifestations of butorphanol overdose are those of opioid drugs in general. The most serious symptoms are hypoventilation, cardiovascular insufficiency, coma, and death.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Butorphanol.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Butorphanol.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Butorphanol.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Butorphanol is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Butorphanol is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Butorphanol.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Butorphanol is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Agomelatine.Approved, Investigational
AlaproclateButorphanol may increase the serotonergic activities of Alaproclate.Experimental
AlcuroniumThe risk or severity of adverse effects can be increased when Alcuronium is combined with Butorphanol.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Butorphanol is combined with Alfentanil.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Butorphanol.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Butorphanol.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Butorphanol is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Amiloride.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Amitriptyline.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Butorphanol which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Butorphanol is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Butorphanol.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Butorphanol.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Butorphanol is combined with Aripiprazole.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Asenapine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium is combined with Butorphanol.Experimental
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Butorphanol.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Butorphanol.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Azaperone.Vet Approved
AzelastineButorphanol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Butorphanol is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Butorphanol is combined with Barbital.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Butorphanol.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Butorphanol.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Butorphanol.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Butorphanol is combined with Benzyl alcohol.Approved
BezitramideButorphanol may decrease the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Butorphanol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Butorphanol.Investigational
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Butorphanol.Experimental
BrexpiprazoleThe risk or severity of adverse effects can be increased when Butorphanol is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Butorphanol is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Bupivacaine.Approved, Investigational
BuprenorphineButorphanol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Butorphanol.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Butorphanol.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butorphanol is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butorphanol is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butorphanol is combined with Butethal.Approved, Illicit
CanertinibThe risk or severity of adverse effects can be increased when Butorphanol is combined with Canertinib.Investigational
Canrenoic acidThe risk or severity of adverse effects can be increased when Butorphanol is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Canrenone.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Butorphanol.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Butorphanol is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Caroxazone.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Butorphanol.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chloroprocaine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Butorphanol.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Butorphanol.Illicit, Withdrawn
ChlorproethazineChlorproethazine may increase the hypotensive activities of Butorphanol.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Butorphanol.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorzoxazone.Approved
CicletanineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cicletanine.Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cinchocaine.Approved, Vet Approved
CitalopramButorphanol may increase the serotonergic activities of Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clobazam.Approved, Illicit
ClofenamideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clofenamide.Experimental
clomethiazoleThe risk or severity of adverse effects can be increased when Butorphanol is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clonidine.Approved
ClopamideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clopamide.Experimental
ClopenthixolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clorazepate.Approved, Illicit
ClorexoloneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clorexolone.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Butorphanol.Approved
CocaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Butorphanol.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Butorphanol is combined with Conivaptan.Approved, Investigational
CyclizineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cyclobenzaprine.Approved
CyclopenthiazideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cyclopenthiazide.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Butorphanol.Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dapiprazole.Approved
DapoxetineButorphanol may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Butorphanol.Approved, Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Desmopressin.Approved
DesvenlafaxineButorphanol may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Butorphanol.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Butorphanol.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Diazepam.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Butorphanol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Butorphanol is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may increase the analgesic activities of Butorphanol.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Butorphanol is combined with Diphenoxylate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Butorphanol is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Drotebanol.Experimental, Illicit
DuloxetineButorphanol may increase the serotonergic activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Butorphanol is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Efonidipine.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Eltanolone.Investigational
EluxadolineButorphanol may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Butorphanol.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Enflurane.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Butorphanol is combined with Entacapone.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Eplerenone.Approved
EscitalopramButorphanol may increase the serotonergic activities of Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Butorphanol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Butorphanol is combined with Etacrynic acid.Approved
EtanautineThe risk or severity of adverse effects can be increased when Etanautine is combined with Butorphanol.Experimental
EthanolButorphanol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Butorphanol.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Butorphanol is combined with Etomidate.Approved
EtoperidoneButorphanol may increase the serotonergic activities of Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with Butorphanol.Experimental
EzogabineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Butorphanol is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenquizoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fenquizone.Experimental
FentanylThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Butorphanol.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Flunitrazepam.Approved, Illicit
FluoxetineButorphanol may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fluspirilene.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fospropofol.Approved, Illicit
FurazolidoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Furazolidone.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Butorphanol is combined with Gabapentin Enacarbil.Approved
GallamineThe risk or severity of adverse effects can be increased when Gallamine is combined with Butorphanol.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Butorphanol.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Butorphanol is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepefrineGepefrine may increase the analgesic activities of Butorphanol.Experimental
GepironeThe risk or severity of adverse effects can be increased when Butorphanol is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Butorphanol.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Butorphanol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Butorphanol.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Butorphanol is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Butorphanol.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Hydracarbazine.Experimental
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneButorphanol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Butorphanol.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may increase the analgesic activities of Butorphanol.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Butorphanol.Approved
IbopamineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ibopamine.Experimental
IloperidoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Imipramine.Approved
IndalpineButorphanol may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Indapamide.Approved
IndiplonThe risk or severity of adverse effects can be increased when Butorphanol is combined with Indiplon.Investigational
Iofetamine I-123Iofetamine I-123 may increase the analgesic activities of Butorphanol.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Butorphanol.Approved
IproclozideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Butorphanol is combined with Iproniazid.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Butorphanol is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Isoflurane.Approved, Vet Approved
IsosorbideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Isosorbide.Approved
KetamineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ketobemidone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Butorphanol is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Butorphanol is combined with Levomethadyl Acetate.Approved
LevomilnacipranButorphanol may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Lidocaine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Butorphanol.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Butorphanol is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Butorphanol is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Butorphanol.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Butorphanol.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Maprotiline.Approved
MazaticolThe risk or severity of adverse effects can be increased when Mazaticol is combined with Butorphanol.Experimental
MebanazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Butorphanol is combined with Mebicar.Experimental
MebutizideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Mebutizide.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Butorphanol.Approved
MeclizineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Medetomidine.Vet Approved
MefrusideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Mefruside.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Butorphanol is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Melperone.Approved
MephedroneMephedrone may increase the analgesic activities of Butorphanol.Investigational
MephentermineMephentermine may increase the analgesic activities of Butorphanol.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Butorphanol.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Meptazinol.Experimental
MersalylThe risk or severity of adverse effects can be increased when Butorphanol is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Butorphanol.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Butorphanol.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Butorphanol.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Butorphanol.Approved
MethotrimeprazineButorphanol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methoxyflurane.Approved, Vet Approved
MethoxyphenamineMethoxyphenamine may increase the analgesic activities of Butorphanol.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methyclothiazide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methylecgonine.Experimental
Methylene blueMethylene blue may increase the hypotensive activities of Butorphanol.Investigational
MethylnaltrexoneThe risk or severity of adverse effects can be increased when Methylnaltrexone is combined with Butorphanol.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methylphenobarbital.Approved
MeticraneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Meticrane.Experimental
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Butorphanol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Metolazone.Approved
MetyrosineButorphanol may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Midazolam.Approved, Illicit
Midomafetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Butorphanol.Experimental, Illicit
MilnacipranButorphanol may increase the serotonergic activities of Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.Approved, Investigational
MirtazapineButorphanol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMMDA may increase the analgesic activities of Butorphanol.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Moclobemide.Approved
MolindoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Butorphanol.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Butorphanol.Approved, Investigational
MuzolimineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Muzolimine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Nalbuphine.Approved
NaloxegolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Naloxegol.Approved
NaltrexoneThe therapeutic efficacy of Butorphanol can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodoneButorphanol may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NialamideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Nialamide.Withdrawn
NicomorphineButorphanol may decrease the analgesic activities of Nicomorphine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Nitrous oxide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Nortriptyline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Butorphanol.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Butorphanol is combined with Opium.Approved, Illicit
OrphenadrineButorphanol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Butorphanol is combined with Osanetant.Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Butorphanol.Experimental
OxazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Oxazepam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Oxethazaine.Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Butorphanol.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Butorphanol is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Oxybuprocaine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Butorphanol.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Butorphanol.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Butorphanol.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Paliperidone.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Butorphanol.Approved
ParaldehydeButorphanol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pargyline.Approved
ParoxetineButorphanol may increase the serotonergic activities of Paroxetine.Approved, Investigational
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Butorphanol.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Butorphanol.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Butorphanol.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.Approved
PerazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Butorphanol is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Butorphanol.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Phenelzine.Approved
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Butorphanol.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Butorphanol is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Butorphanol is combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Phenoxypropazine.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Butorphanol.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pipamperone.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Butorphanol.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Butorphanol.Approved
PiretanideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pirlindole.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pomalidomide.Approved
PotassiumThe risk or severity of adverse effects can be increased when Butorphanol is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Butorphanol is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleButorphanol may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Butorphanol.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Butorphanol.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Butorphanol.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Butorphanol.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Butorphanol is combined with Propanidid.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Butorphanol.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Proparacaine.Approved, Vet Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Butorphanol.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Butorphanol.Investigational
PropofolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Butorphanol is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Butorphanol is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Butorphanol.Approved
QuazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Quetiapine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Quinethazone.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Butorphanol.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ramelteon.Approved, Investigational
RamosetronButorphanol may increase the constipating activities of Ramosetron.Approved
RasagilineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Butorphanol is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Butorphanol.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Butorphanol.Investigational
RolofyllineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Romifidine.Vet Approved
RopiniroleButorphanol may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ropivacaine.Approved
RotigotineButorphanol may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Butorphanol.Approved
SafrazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Safrazine.Withdrawn
ScopolamineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Butorphanol.Approved, Vet Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Butorphanol.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Butorphanol is combined with Sertindole.Approved, Withdrawn
SertralineButorphanol may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Sevoflurane.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Butorphanol.Approved
SpiradolineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Spiradoline.Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Butorphanol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Butorphanol is combined with Sufentanil.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Sulpiride.Approved
SultoprideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Sultopride.Experimental
SuvorexantButorphanol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Butorphanol.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tetrodotoxin.Investigational
ThalidomideButorphanol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Theobromine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Butorphanol is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Butorphanol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Butorphanol.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Butorphanol is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Thioridazine.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tiapride.Approved, Investigational
TicrynafenThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tilidine.Experimental
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Butorphanol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Toloxatone.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Butorphanol.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Butorphanol is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Butorphanol.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Trazodone.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Triazolam.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Butorphanol.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Butorphanol.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Triprolidine.Approved
TropatepineThe risk or severity of adverse effects can be increased when Tropatepine is combined with Butorphanol.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Butorphanol.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Butorphanol.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Butorphanol.Approved
UlaritideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ularitide.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Butorphanol is combined with Valproic Acid.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Butorphanol.Approved
VenlafaxineButorphanol may increase the serotonergic activities of Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Butorphanol is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Butorphanol is combined with Xenon.Experimental
XipamideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Xipamide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Butorphanol is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ziconotide.Approved
ZimelidineButorphanol may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Butorphanol.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Zolazepam.Vet Approved
ZolpidemButorphanol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.

References

Synthesis Reference

Monkovic, I. and Conway, T.T.; U.S. Patent 3,775,414; November 27,1973; Monkovic, I.,Wong, H. and Lim, G.; U.S. Patent 3,980,641; September 14, 1976; Pachter, IJ., Belleau, B.R. and Monkovic, I.; U.S. Patent 3,819,635; June 25,1974; and Lim, G. and Hooper, J.W.; U.S. Patent 4,017,497; April 12,1977; all assigned to Bristol-Myers Company.

General References
  1. Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH, Levine JD: The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain. Pain. 1999 Nov;83(2):339-45. [PubMed:10534607 ]
  2. Fan LW, Tanaka S, Tien LT, Ma T, Rockhold RW, Ho IK: Withdrawal from dependence upon butorphanol uniquely increases kappa(1)-opioid receptor binding in the rat brain. Brain Res Bull. 2002 Jun;58(2):149-60. [PubMed:12127012 ]
External Links
KEGG Drug
D00837
KEGG Compound
C06863
PubChem Compound
6916249
PubChem Substance
46507553
ChemSpider
16735714
BindingDB
50240437
ChEBI
3242
ChEMBL
CHEMBL33986
Therapeutic Targets Database
DAP000214
PharmGKB
PA164745398
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Butorphanol
ATC Codes
N02AF01 — Butorphanol
AHFS Codes
  • 28:08.12
PDB Entries
Not Available
FDA label
Download (320 KB)
MSDS
Download (60.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentCurettage / Pregnancy termination therapy1
4CompletedTreatmentHysterectomy / Postoperative pain1
4CompletedTreatmentPostoperative pain1
Not AvailableCompletedPreventionAnaesthesia therapy / Pain1
Not AvailableUnknown StatusTreatmentLabour Pain1

Pharmacoeconomics

Manufacturers
  • Bedford laboratories div ben venue laboratories inc
  • Claris lifesciences ltd
  • Hikma farmaceutica (portugal) sa
  • Hikma farmaceutica sa
  • Hospira inc
  • Apothecon inc div bristol myers squibb
  • Mylan pharmaceuticals inc
  • Novex pharma
  • Roxane laboratories inc
  • Bristol myers squibb co pharmaceutical research institute
Packagers
Dosage forms
FormRouteStrength
SolutionNasal10 mg
InjectionIntramuscular; Intravenous1 mg/mL
InjectionIntramuscular; Intravenous2 mg/mL
Injection, solutionIntramuscular; Intravenous1 mg/mL
Injection, solutionIntramuscular; Intravenous2 mg/mL
SprayNasal10 mg/mL
Spray, meteredNasal10 mg/mL
SprayNasal10 mg
Aerosol, metered; liquidNasal10 mg
Prices
Unit descriptionCostUnit
Butorphanol Tartrate 10 mg/ml Solution 2.5ml Bottle56.99USD bottle
Butorphanol 10 mg/ml spray39.63USD ml
Stadol 2 mg/ml vial10.11USD ml
Butorphanol 2 mg/ml vial7.2USD ml
Butorphanol 1 mg/ml vial3.6USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)272-274Monkovic, I. and Conway, T.T.; U.S. Patent 3,775,414; November 27,1973; Monkovic, I.,Wong, H. and Lim, G.; U.S. Patent 3,980,641; September 14, 1976; Pachter, IJ., Belleau, B.R. and Monkovic, I.; U.S. Patent 3,819,635; June 25,1974; and Lim, G. and Hooper, J.W.; U.S. Patent 4,017,497; April 12,1977; all assigned to Bristol-Myers Company.
water solubilityModerateNot Available
logP3.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.16 mg/mLALOGPS
logP3.65ALOGPS
logP2.89ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)9.86ChemAxon
pKa (Strongest Basic)10.7ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area43.7 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity95.92 m3·mol-1ChemAxon
Polarizability37.94 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9798
Blood Brain Barrier+0.9463
Caco-2 permeable+0.6844
P-glycoprotein substrateSubstrate0.8494
P-glycoprotein inhibitor IInhibitor0.5
P-glycoprotein inhibitor IIInhibitor0.5667
Renal organic cation transporterInhibitor0.6508
CYP450 2C9 substrateNon-substrate0.8248
CYP450 2D6 substrateSubstrate0.509
CYP450 3A4 substrateSubstrate0.5842
CYP450 1A2 substrateNon-inhibitor0.6532
CYP450 2C9 inhibitorNon-inhibitor0.9094
CYP450 2D6 inhibitorInhibitor0.6572
CYP450 2C19 inhibitorNon-inhibitor0.8456
CYP450 3A4 inhibitorNon-inhibitor0.8744
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9017
Ames testNon AMES toxic0.7587
CarcinogenicityNon-carcinogens0.9573
BiodegradationNot ready biodegradable0.9368
Rat acute toxicity2.6466 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5378
hERG inhibition (predictor II)Inhibitor0.5983
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenanthrenes and derivatives. These are polycyclic compounds containing a phenanthrene moiety, which is a tricyclic aromatic compound with three non-linearly fused benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenanthrenes and derivatives
Sub Class
Not Available
Direct Parent
Phenanthrenes and derivatives
Alternative Parents
Benzazocines / Tetralins / Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Piperidines / Tertiary alcohols / Trialkylamines / Cyclic alcohols and derivatives / 1,2-aminoalcohols / Azacyclic compounds
show 2 more
Substituents
Phenanthrene / Benzazocine / Tetralin / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Piperidine / Cyclic alcohol / Tertiary alcohol / 1,2-aminoalcohol / Tertiary amine
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
morphinane alkaloid (CHEBI:3242 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name
OPRK1
Uniprot ID
P41145
Uniprot Name
Kappa-type opioid receptor
Molecular Weight
42644.665 Da
References
  1. Vivian JA, DeYoung MB, Sumpter TL, Traynor JR, Lewis JW, Woods JH: kappa-Opioid receptor effects of butorphanol in rhesus monkeys. J Pharmacol Exp Ther. 1999 Jul;290(1):259-65. [PubMed:10381785 ]
  2. Park Y, Jang CG, Ho IK, Ko KH: kappa-opioid agonist stimulated regional distribution of [(35)S]GTPgammas binding in butorphanol continuously infused rat. Brain Res Bull. 2000 May 1;52(1):17-20. [PubMed:10779697 ]
  3. Fan LW, Tanaka S, Tien LT, Ma T, Rockhold RW, Ho IK: Withdrawal from dependence upon butorphanol uniquely increases kappa(1)-opioid receptor binding in the rat brain. Brain Res Bull. 2002 Jun;58(2):149-60. [PubMed:12127012 ]
  4. Fan LW, Tanaka S, Park Y, Sasaki K, Ma T, Tien LT, Rockhold RW, Ho IK: Butorphanol dependence and withdrawal decrease hippocampal kappa 2-opioid receptor binding. Brain Res. 2002 Dec 27;958(2):277-90. [PubMed:12470863 ]
  5. Commiskey S, Fan LW, Ho IK, Rockhold RW: Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16. Epub 2005 Jun 8. [PubMed:15942128 ]
  6. Picker MJ, Benyas S, Horwitz JA, Thompson K, Mathewson C, Smith MA: Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists. J Pharmacol Exp Ther. 1996 Dec;279(3):1130-41. [PubMed:8968334 ]
  7. Wakabayashi H, Tokuyama S, Ho IK: Simultaneous measurement of biogenic amines and their metabolites in rat brain regions after acute administration of and abrupt withdrawal from butorphanol or morphine. Neurochem Res. 1995 Oct;20(10):1179-85. [PubMed:8746803 ]
  8. Narita M, Feng Y, Makimura M, Hoskins B, Ho IK: Repeated administration of opioids alters characteristics of membrane-bound phorbol ester binding in rat brain. Eur J Pharmacol. 1994 Dec 27;271(2-3):547-50. [PubMed:7705457 ]
  9. Ohta S, Niwa M, Nozaki M, Tsurumi K, Shimonaka H, Tanahashi T, Uematsu H, Yamamoto M, Fujimura H: [Kappa-type opioid receptor in human placental membrane]. Masui. 1989 Oct;38(10):1293-300. [PubMed:2555580 ]
  10. Walsh SL, Chausmer AE, Strain EC, Bigelow GE: Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade. Psychopharmacology (Berl). 2008 Jan;196(1):143-55. Epub 2007 Oct 2. [PubMed:17909753 ]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name
OPRD1
Uniprot ID
P41143
Uniprot Name
Delta-type opioid receptor
Molecular Weight
40368.235 Da
References
  1. Fan LW, Tanaka S, Tien LT, Ma T, Rockhold RW, Ho IK: Withdrawal from dependence upon butorphanol uniquely increases kappa(1)-opioid receptor binding in the rat brain. Brain Res Bull. 2002 Jun;58(2):149-60. [PubMed:12127012 ]
  2. Fan LW, Tanaka S, Park Y, Sasaki K, Ma T, Tien LT, Rockhold RW, Ho IK: Butorphanol dependence and withdrawal decrease hippocampal kappa 2-opioid receptor binding. Brain Res. 2002 Dec 27;958(2):277-90. [PubMed:12470863 ]
  3. Commiskey S, Fan LW, Ho IK, Rockhold RW: Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16. Epub 2005 Jun 8. [PubMed:15942128 ]
  4. Picker MJ, Benyas S, Horwitz JA, Thompson K, Mathewson C, Smith MA: Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists. J Pharmacol Exp Ther. 1996 Dec;279(3):1130-41. [PubMed:8968334 ]
  5. Wakabayashi H, Tokuyama S, Ho IK: Simultaneous measurement of biogenic amines and their metabolites in rat brain regions after acute administration of and abrupt withdrawal from butorphanol or morphine. Neurochem Res. 1995 Oct;20(10):1179-85. [PubMed:8746803 ]
  6. Narita M, Feng Y, Makimura M, Hoskins B, Ho IK: Repeated administration of opioids alters characteristics of membrane-bound phorbol ester binding in rat brain. Eur J Pharmacol. 1994 Dec 27;271(2-3):547-50. [PubMed:7705457 ]
  7. Walsh SL, Chausmer AE, Strain EC, Bigelow GE: Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade. Psychopharmacology (Berl). 2008 Jan;196(1):143-55. Epub 2007 Oct 2. [PubMed:17909753 ]
  8. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Details
3. Mu-type opioid receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Partial antagonist
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. Vivian JA, DeYoung MB, Sumpter TL, Traynor JR, Lewis JW, Woods JH: kappa-Opioid receptor effects of butorphanol in rhesus monkeys. J Pharmacol Exp Ther. 1999 Jul;290(1):259-65. [PubMed:10381785 ]
  2. Fan LW, Tanaka S, Tien LT, Ma T, Rockhold RW, Ho IK: Withdrawal from dependence upon butorphanol uniquely increases kappa(1)-opioid receptor binding in the rat brain. Brain Res Bull. 2002 Jun;58(2):149-60. [PubMed:12127012 ]
  3. Fan LW, Tanaka S, Park Y, Sasaki K, Ma T, Tien LT, Rockhold RW, Ho IK: Butorphanol dependence and withdrawal decrease hippocampal kappa 2-opioid receptor binding. Brain Res. 2002 Dec 27;958(2):277-90. [PubMed:12470863 ]
  4. Commiskey S, Fan LW, Ho IK, Rockhold RW: Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16. Epub 2005 Jun 8. [PubMed:15942128 ]
  5. Picker MJ, Benyas S, Horwitz JA, Thompson K, Mathewson C, Smith MA: Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists. J Pharmacol Exp Ther. 1996 Dec;279(3):1130-41. [PubMed:8968334 ]
  6. Wakabayashi H, Tokuyama S, Ho IK: Simultaneous measurement of biogenic amines and their metabolites in rat brain regions after acute administration of and abrupt withdrawal from butorphanol or morphine. Neurochem Res. 1995 Oct;20(10):1179-85. [PubMed:8746803 ]
  7. Picker MJ: Discriminative stimulus effects of the mixed-opioid agonist/antagonist dezocine: cross-substitution by mu and delta opioid agonists. J Pharmacol Exp Ther. 1997 Dec;283(3):1009-17. [PubMed:9399970 ]
  8. Narita M, Feng Y, Makimura M, Hoskins B, Ho IK: Repeated administration of opioids alters characteristics of membrane-bound phorbol ester binding in rat brain. Eur J Pharmacol. 1994 Dec 27;271(2-3):547-50. [PubMed:7705457 ]
  9. Walsh SL, Chausmer AE, Strain EC, Bigelow GE: Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade. Psychopharmacology (Berl). 2008 Jan;196(1):143-55. Epub 2007 Oct 2. [PubMed:17909753 ]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:41